Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4223 Target Snapshot

Tyrosine-protein kinase FRK · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,628Compounds
261Assays
35Approved Drugs
980.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Tyrosine-protein kinase FRK shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P42685. Start with cancer, then reuse UniProt P42685 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P42685 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
cancer

Tyrosine-protein kinase FRK shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include REGORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase FRK as ChEMBL target CHEMBL4223, mapped to UniProt P42685. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase FRK
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4223
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P42685
Tyrosine-protein kinase FRK
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase FRK is the right protein anchor across sources, using UniProt P42685 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTyrosine-protein kinase FRK
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP42685
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase FRK
UniProt AccessionP42685
Component TypeProtein
Sequence Length505 aa

Tyrosine-protein kinase FRK

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase FRK, mapped to UniProt P42685. Sequence length is 505 aa.

Mapped IDP42685
Review nameTyrosine-protein kinase FRK
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Tyrosine-protein kinase FRK shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
colorectal adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
colorectal cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
colorectal carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
colorectal neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include REGORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

35
Approved
14
Phase III
25
Phase II
11
Phase I
Assay Mix

Activity Type Distribution

IC5082.0
KI497.0
KD401.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5416410 9.51 Kd 0.31 Approved
CHEMBL1984162 9.0 Ki 1.0 Preclinical
CHEMBL1993661 9.0 Ki 1.0 Preclinical
CHEMBL400402 9.0 Kd 1.0 Preclinical
CHEMBL1981047 8.9 Ki 1.259 Preclinical
CHEMBL1171837 8.89 IC50 1.3 Approved
CHEMBL288441 8.85 Kd 1.4 Approved
CHEMBL1980297 8.7 Ki 1.995 Clinical
CHEMBL1992306 8.7 Ki 1.995 Preclinical
CHEMBL288441 8.66 IC50 2.2 Approved
Distribution

pChEMBL Value Distribution

11
5.0
80
5.5
101
6.0
51
6.5
58
7.0
47
7.5
19
8.0
13
8.5
3
9.0
3
9.5
pChEMBL
Approved Drugs

Approved Drugs

TOVORAFENIB
CHEMBL3348923
Approved 2024
Properties Compare Identifier
ZANUBRUTINIB
CHEMBL3936761
Approved 2019
Properties Compare Identifier
ENTRECTINIB
CHEMBL1983268
Approved 2019
Properties Compare Identifier
FEDRATINIB
CHEMBL1287853
Approved 2019
Properties Compare Identifier
LORLATINIB
CHEMBL3286830
Approved 2018
Properties Compare Identifier
BRIGATINIB
CHEMBL3545311
Approved 2017
Properties Compare Identifier
TIVOZANIB
CHEMBL1289494
Approved 2017
Properties Compare Identifier
DABRAFENIB
CHEMBL2028663
Approved 2013
Properties Compare Identifier
IBRUTINIB
CHEMBL1873475
Approved 2013
Properties Compare Identifier
PONATINIB
CHEMBL1171837
Approved 2012
Properties Compare Identifier
CABOZANTINIB
CHEMBL2105717
Approved 2012
Properties Compare Identifier
BOSUTINIB
CHEMBL288441
Approved 2012
Properties Compare Identifier
VANDETANIB
CHEMBL24828
Approved 2011
Properties Compare Identifier
CRIZOTINIB
CHEMBL601719
Approved 2011
Properties Compare Identifier
PAZOPANIB
CHEMBL477772
Approved 2009
Properties Compare Identifier
NILOTINIB
CHEMBL255863
Approved 2007
Properties Compare Identifier
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
Properties Compare Identifier
SUNITINIB
CHEMBL535
Approved 2006
Properties Compare Identifier
DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
SORAFENIB
CHEMBL1336
Approved 2005
Properties Compare Identifier
ERLOTINIB
CHEMBL553
Approved 2004
Properties Compare Identifier
GEFITINIB
CHEMBL939
Approved 2003
Properties Compare Identifier
IMATINIB
CHEMBL941
Approved 2001
Properties Compare Identifier
Assay Landscape

Assay Landscape

261
Total Assays
193
Tested Compounds
3
Assay Types
Binding — 259 assays, 130 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 208 90 6.6
assay format 36 6 7.2
cell-based format 14 4 6.8
subcellular format 1 30 6.4
ADME — 1 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 2 6.8
Functional — 1 assays, 193 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 193 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine